Healthcare provider profile · identity verified

Gary L Kobayashi, M.D.

Internal Medicine · VISTA, CA · NPI 1245303353

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	480	145
Amlodipine Besylate	Amlodipine Besylate	362	114
Lisinopril	Lisinopril	288	90
Losartan Potassium	Losartan Potassium	227	71
Levothyroxine Sodium	Levothyroxine Sodium	221	71
Metformin Hcl	Metformin Hcl	204	68
Gabapentin	Gabapentin	152	52
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	138	24
Valsartan	Valsartan	120	32
Metoprolol Succinate	Metoprolol Succinate	119	42
Pravastatin Sodium	Pravastatin Sodium	115	34
Simvastatin	Simvastatin	111	29
Eliquis	Apixaban	106	29
Hydrochlorothiazide	Hydrochlorothiazide	92	32
Ozempic	Semaglutide	90	15
Alendronate Sodium	Alendronate Sodium	88	28
Rosuvastatin Calcium	Rosuvastatin Calcium	88	26
Doxazosin Mesylate	Doxazosin Mesylate	85	22
Tamsulosin Hcl	Tamsulosin Hcl	85	28
Omeprazole	Omeprazole	80	30
Trazodone Hcl	Trazodone Hcl	80	27
Albuterol Sulfate Hfa	Albuterol Sulfate	75	24
Carvedilol	Carvedilol	75	20
Hydralazine Hcl	Hydralazine Hcl	74	24
Furosemide	Furosemide	72	27
Alprazolam	Alprazolam	68	21
Atenolol	Atenolol	64	22
Pantoprazole Sodium	Pantoprazole Sodium	64	21
Allopurinol	Allopurinol	63	18
Benazepril Hcl	Benazepril Hcl	61	18
Finasteride	Finasteride	61	14
Olmesartan Medoxomil	Olmesartan Medoxomil	56	16
Lovastatin	Lovastatin	55	16
Spironolactone	Spironolactone	55	16
Ezetimibe	Ezetimibe	53	14
Triamcinolone Acetonide	Triamcinolone Acetonide	52	22
Escitalopram Oxalate	Escitalopram Oxalate	51	18
Duloxetine Hcl	Duloxetine Hcl	50	11
Metoprolol Tartrate	Metoprolol Tartrate	48	17
Tramadol Hcl	Tramadol Hcl	47	suppressed
Lorazepam	Lorazepam	44	11
Trulicity	Dulaglutide	44	12
Jardiance	Empagliflozin	43	suppressed
Rybelsus	Semaglutide	43	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	42	12
Bupropion Xl	Bupropion Hcl	39	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	39	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	38	suppressed
Citalopram Hbr	Citalopram Hydrobromide	37	12
Potassium Chloride	Potassium Chloride	37	16
Famotidine	Famotidine	36	11
Glimepiride	Glimepiride	36	suppressed
Glipizide	Glipizide	35	12
Metformin Hcl Er	Metformin Hcl	34	11
Clonazepam	Clonazepam	31	suppressed
Clopidogrel	Clopidogrel Bisulfate	29	13
Fluticasone Propionate	Fluticasone Propionate	29	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	28	11
Irbesartan	Irbesartan	27	suppressed
Synthroid	Levothyroxine Sodium	27	suppressed
Sildenafil Citrate	Sildenafil Citrate	26	suppressed
Donepezil Hcl	Donepezil Hcl	25	suppressed
Ibuprofen	Ibuprofen	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	suppressed
Oxycodone Hcl	Oxycodone Hcl	25	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	23	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Celecoxib	Celecoxib	22	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	21	suppressed
Breo Ellipta	Fluticasone/Vilanterol	20	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	20	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	20	suppressed
Terazosin Hcl	Terazosin Hcl	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Estradiol	Estradiol	19	suppressed
Meloxicam	Meloxicam	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	11
Clonidine Hcl	Clonidine Hcl	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Bumetanide	Bumetanide	17	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	15
Topiramate	Topiramate	17	suppressed
Azithromycin	Azithromycin	16	14
Doxycycline Hyclate	Doxycycline Hyclate	16	12
Ipratropium Bromide	Ipratropium Bromide	16	suppressed
Sertraline Hcl	Sertraline Hcl	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	13
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	13
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Eszopiclone	Eszopiclone	15	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Glipizide Er	Glipizide	15	suppressed
Arnuity Ellipta	Fluticasone Furoate	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	13	suppressed
Cephalexin	Cephalexin	13	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Digoxin	Digoxin	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Prednisone	Prednisone	13	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Montelukast Sodium	Montelukast Sodium	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Colchicine	Colchicine	11	suppressed
Ibandronate Sodium	Ibandronate Sodium	11	suppressed
Nystatin	Nystatin	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Tresiba Flextouch U-200	Insulin Degludec	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error